Pharma BD Deal Intelligence
Servier paid $1.8B upfront plus $200M in milestones to acquire Agios' entire oncology business—gaining Tibsovo for IDH1-mutant cancers and vorasidenib (later Voranigo) for low-grade glioma. The deal transformed a mid-sized French pharma into a precision oncology company with a mutation-defined franchise.
In this Phase 1 dose-escalation and expansion study of 258 patients with mutant IDH1 relapsed or refractory acute myeloid leukemia, ivosidenib at 500 mg daily…
Agios Pharmaceuticals is selling its oncology business — including approved leukemia drug Tibsovo and an attractive pipeline of IDH-targeted candidates — to…
INDIGO Phase 3 randomized 331 patients with residual or recurrent IDH-mutant low-grade glioma to vorasidenib 40 mg or placebo. Vorasidenib produced a median…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Servier acquired Agios Pharmaceuticals' entire oncology business for up to $2 billion ($1.8 billion upfront plus $200 million in regulatory milestones) plus royalties, gaining Tibsovo (ivosidenib), vorasidenib (brain-penetrant dual IDH1/IDH2 inhibitor), and a portfolio of IDH-mutant oncology assets.
24K US cases/yr · $450M Global IDH-targeted oncology revenue 2020 (Tibsovo + IDHIFA, USD MM) · 30 % of AML cases with IDH1 or IDH2 mutations
Acute myeloid leukemia is the most common acute leukemia in adults with approximately 20,240 new US cases and 11,400 deaths annually (American Cancer Society 2021). IDH1 mutations occur in approximately 6-10% of AML cases and IDH2 mutations in 8-19%, together representing roughly 25-30% of newly diagnosed AML. IDH mutations result in production of the oncometabolite 2-hydroxyglutarate (2-HG), which causes hypermethylation of DNA and histones and blocks myeloid differentiation. Diffuse low-grade glioma (WHO grade 2) affects approximately 4,000-5,000 newly diagnosed US patients annually; over 80% of low-grade gliomas harbor IDH1 mutations (most commonly IDH1-R132H). These tumors typically present in patients aged 30-50 with seizures and progress over years to high-grade glioma despite surgery, radiation, and alkylator chemotherapy. There has been no targeted therapy approved for IDH-mutant glioma at deal date — the standard of care is surgery followed by watchful waiting or PCV/temozolomide. Vorasidenib's brain-penetrant dual IDH1/IDH2 inhibition (Phase 3 INDIGO ongoing at deal date) addresses a clear unmet need; vorasidenib went on to demonstrate a 39.4-month median progression-free survival vs 11.1 months for placebo (HR 0.39, p<0.001) in INDIGO at ASCO/NEJM 2023.
At deal date (Dec 2020) the IDH-mutant oncology landscape was narrow but consolidating. The only approved IDH inhibitors were Tibsovo (ivosidenib, Agios — IDH1, approved July 2018 for R/R AML and Aug 2019 for newly diagnosed AML in patients ≥75y or with comorbidities; cholangiocarcinoma approval came Aug 2021 post-deal), and IDHIFA (enasidenib, Agios/Celgene-BMS — IDH2, approved Aug 2017 for R/R AML; commercialized by BMS). Vorasidenib (AG-881, dual IDH1/IDH2, brain-penetrant) was in pivotal Phase 3 INDIGO for IDH-mutant low-grade glioma, with no competitor brain-penetrant IDH inhibitor in clinic. AML competitive context broader: venetoclax + azacitidine (Venclexta, AbbVie/Roche, approved Oct 2020 in newly diagnosed unfit AML — 14.7-month OS in VIALE-A), midostaurin (Rydapt, Novartis, FLT3-ITD/TKD), gilteritinib (Xospata, Astellas, R/R FLT3 AML), CPX-351 (Vyxeos, Jazz, secondary AML), Mylotarg (gemtuzumab ozogamicin, Pfizer, CD33), and glasdegib (Daurismo, Pfizer, hedgehog). Cholangiocarcinoma context: Pemazyre (pemigatinib, Incyte, FGFR2 fusions, approved Apr 2020), Truseltiq (infigratinib, BridgeBio/Helsinn, FGFR2). MAT2A inhibitor AG-270 (now S095033) entered Phase 1 for MTAP-deleted tumors. Servier post-deal added vorasidenib NDA submission and Voranigo approval Aug 2024. The Servier-Agios transaction was the largest pure-oncology asset divestiture of 2020 and consolidated the entire IDH-mutant precision oncology franchise under one commercial owner.
3K US cases/yr · $500M Global IDH-mutant Glioma Market (emerging)
IDH mutations in >80% of grade 2/3 diffuse gliomas. Vorasidenib (Voranigo) became the first targeted therapy approved for IDH-mutant grade 2 glioma in 2024.
Servier Voranigo (vorasidenib, brain-penetrant dual IDH1/2 inhibitor) is the first targeted therapy approved in residual/recurrent grade 2 IDH-mutant glioma after surgery (INDIGO). Competing options remain standard-of-care modalities rather than other targeted agents: radiotherapy plus PCV (procarbazine, lomustine, vincristine) or radiotherapy plus temozolomide alkylator chemotherapy (RTOG 9802 paradigm). Agios/Servier ivosidenib (IDH1-selective inhibitor) has been studied in glioma but Voranigo is the lead asset. No other approved targeted therapy exists in this setting.
3K US cases/yr · $800M Global CCA Market (2024)
IDH1 mutations in ~23% of intrahepatic cholangiocarcinoma. Ivosidenib was first targeted therapy for previously treated IDH1-mutant CCA (ClarIDHy trial).
Servier (Tibsovo for IDH1-CCA), QED/Taiho (Truseltiq for FGFR2-CCA). AZ (durvalumab + chemo) is broader 1L standard.
2K US cases/yr · $3.0B Global AML Market (2024)
IDH1 mutations occur in ~12% of AML. Ivosidenib (Tibsovo) was the first targeted IDH1 inhibitor approved for newly diagnosed and R/R IDH1-mutant AML.
Servier (Tibsovo) IDH1 leader. AbbVie/Genentech (venetoclax) dominates unfit AML. Astellas (gilteritinib, FLT3), BMS (enasidenib, IDH2), Jazz (Vyxeos) compete.
Servier acquired Agios Pharmaceuticals' entire oncology business for up to $2 billion ($1.8 billion upfront plus $200 million in regulatory milestones) plus royalties, gaining Tibsovo (ivosidenib), vorasidenib (brain-penetrant dual IDH1/IDH2 inhibitor), and a portfolio of IDH-mutant oncology assets.
FDA approved Voranigo on Aug 6, 2024 for grade 2 IDH-mutant astrocytoma/oligodendroglioma post-surgery. First targeted therapy for low-grade glioma; key asset from Servier's $2B Agios oncology deal.
Significant transaction at $2,000M. Servier acquired Agios Pharmaceuticals' entire oncology business for up to $2 billion ($1.8 billion upfront plus $200 million in regulatory milestones) plus royalties, gaining Tibsovo (ivosidenib), vo
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. (this deal) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier Pharmaceuticals LLC / Black Diamond Therapeutics, Inc. | 2025 | $780M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2020 deals · Servier Pharmaceuticals LLC deals · Oncology deals